Respiratory and thoracic cancers:
Indications for: Vinorelbine
First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), in combination with cisplatin. As a single agent, for the treatment of patients with metastatic NSCLC.
See full labeling. Give by IV inj over 6–10mins. Monotherapy: 30mg/m2 once weekly. Combination therapy: 25mg/m2 on Days 1, 8, 15, and 22 of a 28-day cycle with cisplatin (100mg/m2) given on Day 1 of each 28-day cycle; or 30mg/m2 once weekly with cisplatin (120mg/m2) given on Days 1 and 29, then every 6 weeks. Dose modifications for toxicities, hepatic impairment: see full labeling.
Risk of myelosuppression. Monitor for infection, and/or fever; obtain CBCs with differentials prior to each dose. Monitor for new or worsening neuropathy. Discontinue if neurotoxicity ≥Grade 2. Interrupt therapy if evidence of pulmonary toxicity or unexplained dyspnea; permanently discontinue if confirmed interstitial pneumonitis or acute respiratory distress syndrome. Hepatic injury or impairment: assess hepatic function prior to and during treatment. Avoid extravasation. Embryo-fetal toxicity. Advise use of effective contraception during and for 6 months (females) and for 3 months (males w. female partners) after last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 9 days after last dose).
May be potentiated by CYP3A inhibitors. Increased risk of granulocytopenia with cisplatin.
Leukopenia, neutropenia, anemia, elevated liver enzymes, nausea, asthenia, constipation, inj site reaction, peripheral neuropathy, vomiting; hepatotoxicity, pulmonary toxicity, bowel obstruction, paralytic ileus.
Formerly known under the brand name Navelbine.